Brentuximab Vedotin

Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (i) patients with Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or aft...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2013, Vol.19 (1), p.22-27
Hauptverfasser:	Deng, Changchun, Pan, Beiqing, O'Connor, Owen A
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Clinical Trials, Phase II as Topic Drug Evaluation, Preclinical Hematopoietic Stem Cell Transplantation Hodgkin Disease - drug therapy Hodgkin Disease - therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Ki-1 Antigen - immunology Medical sciences Pharmacology. Drug treatments Recurrence Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!